Erythropoiesis Stimulating Agents (ESAs) - Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp)

July 31, 2008 by RecallAware
Filed under: Medicine 

FDA clarifies approved conditions for use of ESAs in patients with cancer and revises dosing directions for the products.

Source:Full Article

Tags:

Comments

Readers of this site appreciate your comments

You must be logged in to post a comment.

References and links to other sites are provided as a courtesy. The recall and safety information provided here is based entirely on manufacturers' and regulatory agencies' press release or other public information. We make no other representations about the accuracy or timeliness of this information